Logo

RGNX

REGENXBIO Inc.

RGNX

REGENXBIO Inc. • NASDAQ
$13.39 ▲ 0.98% (+0.13)
Market Cap $677.79 M
52w High $13.93
52w Low $5.04
Dividend Yield 0%
P/E -3.87
Volume 1.10M
Outstanding Shares 50.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $29.733M ▲ $20.318M ▼ $-61.941M ▲ -208.324% ▲ $-1.2 ▲ $-44.886M ▲
Q2-2025 $21.359M ▼ $75.523M ▲ $-70.871M ▼ -331.809% ▼ $-1.38 ▼ $-55.973M ▼
Q1-2025 $89.012M ▲ $73.449M ▲ $6.083M ▲ 6.834% ▲ $0.12 ▲ $18.608M ▲
Q4-2024 $21.214M ▼ $66.264M ▼ $-51.186M ▲ -241.284% ▲ $-1.01 ▲ $-37.746M ▲
Q3-2024 $24.197M $73.888M $-59.597M -246.299% $-1.17 $-54.816M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $274.205M ▼ $525.203M ▼ $363.751M ▼ $161.452M ▼
Q2-2025 $323.298M ▲ $581.027M ▲ $367.348M ▲ $213.679M ▼
Q1-2025 $267.869M ▲ $490.929M ▲ $216.732M ▲ $274.197M ▲
Q4-2024 $234.687M ▼ $465.989M ▼ $206.338M ▼ $259.651M ▼
Q3-2024 $255.46M $519.114M $217.698M $301.416M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-61.941M ▲ $-55.96M ▼ $42.287M ▲ $-7.083M ▼ $-20.756M ▲ $-56.451M ▼
Q2-2025 $-70.871M ▼ $-49.342M ▼ $-140.436M ▼ $139.232M ▲ $-50.546M ▼ $-49.733M ▼
Q1-2025 $6.083M ▲ $33.629M ▲ $44.743M ▲ $-5.794M ▲ $72.578M ▲ $32.605M ▲
Q4-2024 $-51.186M ▲ $-31.624M ▲ $40.273M ▼ $-7.74M ▲ $909K ▲ $-32.703M ▲
Q3-2024 $-59.597M $-40.549M $50.258M $-10.857M $-1.148M $-40.875M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License and Service
License and Service
 $20.00M ▲$90.00M ▲$20.00M ▼$20.00M ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue is relatively small and lumpy, reflecting milestone and licensing-driven income rather than steady product sales. The company had a profitable year a few years ago when it booked substantial partnership or licensing revenue, but has since returned to meaningful losses as R&D and operating costs outweigh incoming revenue. Overall, the business is still firmly in the investment and development phase: spending heavily on research and clinical programs, with no mature product base yet to consistently cover those costs.

Balance Sheet

Balance Sheet The balance sheet shows a clear transition from a stronger, cash-rich position a few years ago to a leaner profile today. Cash and total assets have stepped down over time, while shareholder equity has also shrunk as losses accumulate. Debt is present but not dominant, which limits financial strain from interest, yet the cushion of cash and assets is thinner than before. In short, the company still has resources, but its financial safety margin has narrowed and depends heavily on future funding events and partnership inflows.

Cash Flow

Cash Flow Operating cash flow has generally been negative, consistent with a clinical-stage biotech funding trials and development work without yet having recurring product revenue. The one standout year of positive cash flow lines up with a strong revenue year, likely from major licensing or milestone receipts, but this has not been repeatable so far. Capital spending has been moderate and appears to be easing, so most cash burn is from operations rather than big infrastructure projects. Free cash flow is consistently negative, highlighting ongoing cash consumption and the need for either new deals, cost discipline, or future capital raises to sustain the pipeline.

Competitive Edge

Competitive Edge REGENXBIO’s edge centers on its NAV gene therapy platform, a large and well-protected patent estate, and a dual model of both developing its own drugs and licensing its vectors to others. Its technology has been validated by high-profile partners and a commercial product using its platform, which adds credibility. Partnerships with larger pharma players and in-house manufacturing capability further strengthen its position. However, gene therapy is a crowded, fast-moving field with significant scientific and regulatory risk, and the company’s success is highly tied to a few key late-stage programs hitting their clinical and regulatory milestones.

Innovation and R&D

Innovation and R&D The company is highly research-driven, with substantial resources devoted to advancing novel gene therapies for eye diseases, Duchenne muscular dystrophy, and rare metabolic disorders. Its NAV platform is versatile and has already been deployed in multiple clinical programs, some in pivotal stages, showing real depth rather than a single-asset story. In-house manufacturing and exploration of new areas like in vivo antibody delivery suggest a long-term innovation mindset. The flip side is that this intensity of R&D spending keeps costs high and pushes out the timeline for potential profitability, making execution on clinical trials and regulatory submissions crucial.

Summary

REGENXBIO is a classic clinical-stage biotech: scientifically ambitious, strongly positioned technologically, and financially dependent on external funding and milestones until products reach market. The income statement reflects recurring losses and sporadic revenue spikes, the balance sheet shows a shrinking yet still meaningful resource base, and cash flows highlight ongoing burn. On the strategic side, the company benefits from a respected gene therapy platform, deep IP, key partnerships, and a maturing pipeline with several important readouts ahead. Future outcomes will hinge on clinical trial success, regulatory approvals, and the company’s ability to manage its cash while pushing its lead programs toward commercialization.

NEWS

November 25, 2025 · 7:05 AM UTC

REGENXBIO to Participate in Upcoming Investor Conference

Read more

November 6, 2025 · 7:05 AM UTC

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Read more

October 30, 2025 · 7:05 AM UTC

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Read more

October 29, 2025 · 7:05 AM UTC

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Read more

October 15, 2025 · 7:05 AM UTC

REGENXBIO to Participate in Upcoming Investor Conferences

Read more